Antisense Pharma GmbH
Records under this name other than the patents Antisense Pharma GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 7 of 7 · Back to Antisense Pharma GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,148,493 | Method for inhibiting “melanoma inhibitory activity” MIA Formerly held Term ended Term ended Oct 5, 2023 · From the USPTO record | Term ended | Term ended Oct 5, 2023 | From the USPTO record |
| US 8,177,775 | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique Lapsed on the fee record Ended May 15, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 15, 2020 | From the USPTO record |
| US 8,097,597 | Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors Lapsed on the fee record Ended Jan 17, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2020 | From the USPTO record |
| US 7,963,956 | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique Lapsed on the fee record Ended Jun 21, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 21, 2019 | From the USPTO record |
| US 8,936,910 | Method for selective oligonucleotide modification Lapsed on the fee record Ended Jan 20, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jan 20, 2019 | From the USPTO record |
| US 8,822,425 | Dosage of oligonucleotides suitable for the treatment of tumors Lapsed on the fee record Ended Sep 2, 2018 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2018 | From the USPTO record |
| US 7,910,563 | Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA Lapsed on the fee record Ended Mar 22, 2015 · From the USPTO record | Lapsed on the fee record | Ended Mar 22, 2015 | From the USPTO record |